AgingResearch.NewsJoin free

Orexigen Therapeutics

CompanyUnited StatesFounded 2002

Wikidata

Orexigen Therapeutics develops 2 assets, the furthest approved (bupropion in Depressive Disorder, Major). Mostly small molecule acting on SLC6A2, SLC6A3 and OPRM1; based in the United States, founded in 2002.

2
Assets
Furthest stage
Approved
14
Trials
0
Signals

Pipeline

2

  • bupropion

    Inhibits norepinephrine and dopamine reuptake, increasing their availability in synapses.

    Approved, Small molecule, SLC6A2, SLC6A3, Depressive Disorder, Major, seasonal affective disorder

  • naltrexone/bupropion

    Combination dopamine/norepinephrine reuptake inhibitor and opioid antagonist suppressing appetite.

    Phase 3, Small molecule, SLC6A2, SLC6A3, cardiovascular disease, obesity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms6
  • Trials15
  • Similar companies6

Intelligence